Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of MRT-2359 in combination with a second-generation AR inhibitor for treatment of Prostate cancer

Next Previous
Trial Profile

A phase II trial of MRT-2359 in combination with a second-generation AR inhibitor for treatment of Prostate cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRT-2359 (Primary) ; Testosterone congener inhibitors
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms MODeFIRe-1

Most Recent Events

  • 24 Feb 2026 Accoridng to a Monte Rosa Therapeutics media release, Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant patients in Q3 2026
  • 31 Dec 2025 New trial record
  • 16 Dec 2025 Accoridng to a Monte Rosa Therapeutics media release, company plans a phase II trial for Prostate cancer in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top